Equity Analysis /

AU : Mach7 Technologies - AGM paints a positive picture

    Scott Power
    Scott Power

    Senior Analyst - Healthcare, Life Science & Technology

    11 November 2021
    Published by

    M7T hosted its AGM today, reconfirming revenue guidance of A$27m for CY21 and a positive EBITDA for FY22. Following a record 1QFY22 in sales orders it appears that M7T’s operations are kicking into gear with a number of new staff appointments, hospitals opening back up for business and the sales team back on the road. The one hiccup is a patent infringement case that has been bought against the company and will be defended. We have made no changes to our forecasts, valuation or target price. Our recommendation remains an Add.